Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
9.46
-0.33 (-3.37%)
At close: Oct 22, 2026, 4:00 PM EDT
9.40
-0.06 (-0.63%)
After-hours: Oct 22, 2026, 7:30 PM EDT
Gossamer Bio Revenue
Gossamer Bio had revenue of $9.24M in the quarter ending June 30, 2026, a decrease of -19.59%. This brings the company's total for the last twelve months to $53.29M, up 32.43% year-over-year. In the year 2025, Gossamer Bio had annual revenue of $48.47M, down -57.74%. That makes Gossamer Bio the 27,505th largest company in the world by revenue and 3,732nd in the United States.
Revenue (ttm)
$53.29M
Revenue Growth
+32.43%
P/S Ratio
1.09
Revenue / Employee
$328,926
Employees
162
Market Cap
57.86M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 48.47M | -66.23M | -57.74% |
| Dec 31, 2024 | 114.70M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 64.09M |
| Werewolf Therapeutics | 21.00M |
| Caribou Biosciences | 10.04M |
| Alterity Therapeutics | 2.50M |
| RenovoRx | 1.98M |
| iBio, Inc. | 100.00K |
GOSS News
- 9 days ago - Gossamer Bio initiated with a Buy at Chardan - TheFly
- 4 weeks ago - Gossamer Bio submits New Drug Application to FDA for seralutinib - TheFly
- 4 weeks ago - Gossamer Bio submits New Drug Application to FDA for seralutinib - TheFly
- 4 weeks ago - Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension - Business Wire
- 4 weeks ago - Gossamer Bio target adjusted to $90 for split at H.C. Wainwright - TheFly
- 5 weeks ago - Gossamer Bio Appoints Greg Ciongoli to Board of Directors - Business Wire
- 5 weeks ago - Gossamer Bio Proxy statement: Proxy filing - Filings
- 5 weeks ago - Gossamer Bio announces effectiveness of 1-for-80 reverse stock split - TheFly